Lipoproteins, VLDL

"Lipoproteins, VLDL" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A class of lipoproteins of very light (0.93-1.006 g/ml) large size (30-80 nm) particles with a core composed mainly of TRIGLYCERIDES and a surface monolayer of PHOSPHOLIPIDS and CHOLESTEROL into which are imbedded the apolipoproteins B, E, and C. VLDL facilitates the transport of endogenously made triglycerides to extrahepatic tissues. As triglycerides and Apo C are removed, VLDL is converted to INTERMEDIATE-DENSITY LIPOPROTEINS, then to LOW-DENSITY LIPOPROTEINS from which cholesterol is delivered to the extrahepatic tissues.

Descriptor ID	D008079
MeSH Number(s)	D10.532.599 D12.776.521.622
Concept/Terms	Lipoproteins, VLDL Lipoproteins, VLDL VLDL Lipoproteins Prebeta-Lipoproteins Prebeta Lipoproteins Very-Low-Density Lipoproteins Lipoproteins, Very-Low-Density Very Low Density Lipoproteins Pre-beta-Lipoproteins Pre beta Lipoproteins Lipoproteins, VLDL2 Lipoproteins, VLDL2 VLDL2 Lipoproteins Lipoprotein VLDL II Lipoproteins, VLDL1 Lipoproteins, VLDL1 VLDL1 Lipoproteins Lipoproteins, VLDL I Lipoproteins, VLDL3 Lipoproteins, VLDL3 VLDL3 Lipoproteins Lipoproteins, VLDL III

Below are MeSH descriptors whose meaning is more general than "Lipoproteins, VLDL".

Chemicals and Drugs [D]
Lipids [D10]
Lipoproteins [D10.532]
Lipoproteins, VLDL [D10.532.599]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Lipoproteins [D12.776.521]
Lipoproteins, VLDL [D12.776.521.622]

Below are MeSH descriptors whose meaning is related to "Lipoproteins, VLDL".

Below are MeSH descriptors whose meaning is more specific than "Lipoproteins, VLDL".

Lipoproteins, VLDL
Cholesterol, VLDL

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lipoproteins, VLDL" by people in this website by year, and whether "Lipoproteins, VLDL" was a major or minor topic of these publications.

Bar chart showing 9 publications over 7 distinct years, with a maximum of 3 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	0	1	1
2004	0	1	1
2007	0	1	1
2008	1	2	3
2011	1	0	1
2013	1	0	1
2016	1	0	1

Below are the most recent publications written about "Lipoproteins, VLDL" by people in Profiles.

Reyes-Soffer G, Pavlyha M, Ngai C, Thomas T, Holleran S, Ramakrishnan R, Karmally W, Nandakumar R, Fontanez N, Obunike J, Marcovina SM, Lichtenstein AH, Matthan NR, Matta J, Maroccia M, Becue F, Poitiers F, Swanson B, Cowan L, Sasiela WJ, Surks HK, Ginsberg HN. Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation. 2017 Jan 24; 135(4):352-362.

View in: PubMed
Thorp JM, Rice MM, Harper M, Klebanoff M, Sorokin Y, Varner MW, Wapner RJ, Caritis SN, Iams JD, Peaceman AM, Mercer BM, Sciscione A, Rouse DJ, Ramin SM, Anderson GB. Advanced lipoprotein measures and recurrent preterm birth. Am J Obstet Gynecol. 2013 Oct; 209(4):342.e1-7.

View in: PubMed
Manning PJ, Jong SA, Ryalls AR, Sutherland WH. Paraoxonase 1 activity in chylomicrons and VLDL: the effect of type 2 diabetes and meals rich in saturated fat and oleic acid. Lipids. 2012 Mar; 47(3):259-67.

View in: PubMed
Goteiner D, Craig RG, Ashmen R, Janal MN, Eskin B, Lehrman N. Endotoxin levels are associated with high-density lipoprotein, triglycerides, and troponin in patients with acute coronary syndrome and angina: possible contributions from periodontal sources. J Periodontol. 2008 Dec; 79(12):2331-9.

View in: PubMed
Furtado JD, Campos H, Appel LJ, Miller ER, Laranjo N, Carey VJ, Sacks FM. Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial. Am J Clin Nutr. 2008 Jun; 87(6):1623-30.

View in: PubMed
Frank PG, Pavlides S, Cheung MW, Daumer K, Lisanti MP. Role of caveolin-1 in the regulation of lipoprotein metabolism. Am J Physiol Cell Physiol. 2008 Jul; 295(1):C242-8.

View in: PubMed
Coleman JD, Prabhu KS, Thompson JT, Reddy PS, Peters JM, Peterson BR, Reddy CC, Vanden Heuvel JP. The oxidative stress mediator 4-hydroxynonenal is an intracellular agonist of the nuclear receptor peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta). Free Radic Biol Med. 2007 Apr 15; 42(8):1155-64.

View in: PubMed
Ikewaki K, Cain W, Thomas F, Shamburek R, Zech LA, Usher D, Brewer HB, Rader DJ. Abnormal in vivo metabolism of apoB-containing lipoproteins in human apoE deficiency. J Lipid Res. 2004 Jul; 45(7):1302-11.

View in: PubMed
Sumner AE, Falkner B, Diffenderfer MR, Barrett PH, Marsh JB. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males. Proc Soc Exp Biol Med. 1999 Sep; 221(4):352-60.

View in: PubMed
Esfahani M, Bigler RD, Alfieri JL, Gressen E, Lund-Katz S, Scerbo L. Lipoproteins upregulate high affinity Fc receptors in human monocytes. Biochem Biophys Res Commun. 1993 Mar 15; 191(2):610-6.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement